| Followers | 239 |
| Posts | 15510 |
| Boards Moderated | 1 |
| Alias Born | 03/29/2014 |
Thursday, August 26, 2021 7:33:03 PM
LL including the bullet point: “some clinical trials require collection and processing of tumor tissue”, is pretty telling.
Since it was your specific question that LL answered, here are her exact words transcribed:
(Floatserve's) Question: Another question we have… you had mentioned in your presentation the importance of having tissue frozen for future analysis. Can you share why you are recommending that? Is that for future treatment options, or what is the purpose of having their tissue frozen for further analysis?
(LL) Answer: So, there are some clinical trials that do require frozen tissue. For instance, for next generation sequencing tests, or kind of a determination of certain biomarkers such as if you have a certain mutation, you may be eligible for certain clinical trials, but you need the tissue to be able assess whether or not the tumor has that mutation.
I must say that the field has been evolving, you know, in terms of what needs to be preserved or not preserved for trials, and I think it’s kind of best to have all options available because of how we kind of analyze and preserve tissues today may be different from what it is five years from now. It’s certainly different than what it was twenty years ago. So I think it would be good to, kind of research what options are potentially available, and to have as many options open as possible. I mean, there are some clinical trials, as many of you know, that are, for instance, that use the actual tumor tissue to make vaccines or other treatments; and without the tumor tissue taken out and processed at the time of surgery, then sometimes patients would not be eligible for that trial. But there are different trials that occur throughout the course of time and at different centers, so I think exploring as many options as possible is probably the best recommendation.
I actually don't recall hearing about any other clinical trial that requires the patient's own individualized frozen tumor tissue (taken at time of surgery) to make a specific vaccine for that patient other than DCVax-L. So I'd have to agree with you that while DCVax was not named, it was strongly insinuated, IMO.
:)
Recent NWBO News
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
